GlycoEra AG

GlycoEra has extensive experience in sugar engineering, protein degradation, and biopharmaceutical development. Building on this knowledge, GlycoEra has developed a platform that enables the production of protein binders with precisely defined sugar structures that utilize the body’s natural degradation processes. The technology allows for the rapid, targeted, and potent degradation of disease-associated circulating proteins, opening up new applications in precision immunology and potential treatments of severe autoimmune diseases. Clinical testing of the first product candidates is planned for the end of 2025. GlycoEra AG has locations in Wädenswil, Switzerland, and Newton, Massachusetts, USA.

GlycoEra AG
Einsiedlerstrasse 34
CH-8820 Wädenswil
+41 44 244 95 95
www.glycoera.com

President and CEO

Co-Founder und CMfO